Level C· Early human research exploring benefitsProspective StudyPubMed

Single-cell RNA sequencing reveals the potential role of estrogen in tuberous sclerosis complex related renal angiomyolipoma.

Liu Y., Wang W., Zheng G., Xu W., Wang Z., Wang X.

Prospective Study on Systemic / IV, published in Discov Oncol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Discov Oncol (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40608217
DOI
10.1007/s12672-025-02909-1

Abstract (original English)

Tuberous sclerosis complex (TSC) is a kind of rare genetic disorder caused by TSC1/TSC2 gene mutations and presented as angiomyolipoma (AML) in kidney. Previous studies have indicated the presence of estrogen-related heterogeneity in TSC, but this aspect has not been extensively explored. In the present study, we employed single-cell RNA sequencing (scRNA-seq) to investigate the estrogen-related heterogeneity in TSC-AML. A total of two female and two male TSC-AML patients were included in this study. Our results revealed the presence of various cell types within the TSC-AML tissue, including macrophages, endothelial cells, dendritic cells, neutrophils, B cells, fibroblasts, and tumor cells. Among the macrophage population, the immune-suppressive C1QC-Macro cells constituted the majority, and these cells were found to be more prevalent in female patients. AUCell analysis showed that estrogen-related pathways were significantly upregulated in C1QC-Macro cells in female patients compared to male patients. Furthermore, CellChat analysis demonstrated that tumor cells in female patients may regulate C1QC-Macro cells through the CXCL signaling pathway (CXCL12-CXCR4). In contrast, male patients exhibited enhanced interactions in stromal remodeling-related signaling pathways. Tumor cells were further categorized into TC1-TC6 subtypes. Notably, tumor cells with stem cell-like and EMT (ep

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research